# An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

> **NCT05876754** · PHASE3 · RECRUITING · sponsor: **Servier Affaires Médicales** · enrollment: 220 (estimated)

## Conditions studied

- Cholangiocarcinoma

## Interventions

- **DRUG:** Ivosidenib Oral Tablet

## Key facts

- **NCT ID:** NCT05876754
- **Lead sponsor:** Servier Affaires Médicales
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-03
- **Primary completion:** 2027-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05876754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05876754, "An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05876754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*